Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1997 Aug;77(2):124–130. doi: 10.1136/adc.77.2.124

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

I Balfour-Lynn 1, N Klein 1, R Dinwiddie 1
PMCID: PMC1717269  PMID: 9301350

Abstract

Accepted 29 April 1997


BACKGROUND—Controlling lung inflammation may be the key to improving morbidity and mortality in cystic fibrosis.
OBJECTIVE—To assess the effects of inhaled corticosteroids on lung inflammation in cystic fibrosis.
DESIGN—Double blind placebo controlled randomised sequence crossover trial. Fluticasone propionate (400 µg/day) was given as a dry powder inhaler for six weeks with a four week washout period before crossover.
OUTCOME MEASURES—Sputum inflammatory markers (interleukin-8, tumour necrosis factor-α (TNF-α) and neutrophil elastase—both free and bound to α1-antiprotease), sputum interleukin-10, lung function, and symptomatology.
SUBJECTS—Twenty three children from a regional cystic fibrosis centre were enrolled into the study, with mean age 10.3 years (range 7 to 17 years) and mean baseline forced expiratory volume in one second (FEV1) of 64% (range 21% to 102%) predicted for sex and height. One patient was excluded for non-compliance to the study protocol.
RESULTS—No significant benefit was shown for the use of fluticasone propionate in any of the outcomes. For sputum interleukin-8 there was an estimated true treatment median difference of 142 pg/ml (95% confidence interval (CI) 8 to 2866 pg/ml) in favour of placebo; while for maximal expiratory flow at 25% (MEF25%) remaining forced vital capacity predicted for sex and height there was a 15 percentage points (pp) (95% CI 4 to 26 pp) mean treatment difference in favour of placebo. Sputum interleukin-10 was undetected in any samples and unaffected by fluticasone propionate. Neither atopic status, baseline FEV1, nor concomitant DNase therapy had any effect on response to treatment.
CONCLUSIONS—Lack of benefit from fluticasone propionate was most likely due to failure of the drug to penetrate the viscid mucus lining the airways. It is suggested a large multicentre trial with higher doses given for a longer time by a different delivery system is required to assess efficacy.



Full Text

The Full Text of this article is available as a PDF (154.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Lloyd A. R. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 1997 Feb 15;349(9050):490–495. doi: 10.1016/s0140-6736(96)07524-1. [DOI] [PubMed] [Google Scholar]
  2. Armstrong D. S., Grimwood K., Carzino R., Carlin J. B., Olinsky A., Phelan P. D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ. 1995 Jun 17;310(6994):1571–1572. doi: 10.1136/bmj.310.6994.1571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aronoff S. C., Quinn F. J., Jr, Carpenter L. S., Novick W. J., Jr Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr. 1994 Dec;125(6 Pt 1):992–997. doi: 10.1016/s0022-3476(05)82022-0. [DOI] [PubMed] [Google Scholar]
  4. Asher M. I., Keil U., Anderson H. R., Beasley R., Crane J., Martinez F., Mitchell E. A., Pearce N., Sibbald B., Stewart A. W. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995 Mar;8(3):483–491. doi: 10.1183/09031936.95.08030483. [DOI] [PubMed] [Google Scholar]
  5. Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  6. Balfour-Lynn I. M., Dinwiddie R. Role of corticosteroids in cystic fibrosis lung disease. J R Soc Med. 1996;89 (Suppl 27):8–13. [PMC free article] [PubMed] [Google Scholar]
  7. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995 Aug;20(2):63–70. doi: 10.1002/ppul.1950200203. [DOI] [PubMed] [Google Scholar]
  8. Bonfield T. L., Konstan M. W., Burfeind P., Panuska J. R., Hilliard J. B., Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995 Sep;13(3):257–261. doi: 10.1165/ajrcmb.13.3.7544594. [DOI] [PubMed] [Google Scholar]
  9. Bonfield T. L., Panuska J. R., Konstan M. W., Hilliard K. A., Hilliard J. B., Ghnaim H., Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111–2118. doi: 10.1164/ajrccm.152.6.8520783. [DOI] [PubMed] [Google Scholar]
  10. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med. 1995 Apr;151(4):939–941. doi: 10.1164/ajrccm.151.4.7697269. [DOI] [PubMed] [Google Scholar]
  11. Cooper P. J., Robertson C. F., Hudson I. L., Phelan P. D. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):16–22. doi: 10.1002/ppul.1950080107. [DOI] [PubMed] [Google Scholar]
  12. Dean T. P., Dai Y., Shute J. K., Church M. K., Warner J. O. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993 Aug;34(2):159–161. doi: 10.1203/00006450-199308000-00010. [DOI] [PubMed] [Google Scholar]
  13. Eigen H., Rosenstein B. J., FitzSimmons S., Schidlow D. V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995 Apr;126(4):515–523. doi: 10.1016/s0022-3476(95)70343-8. [DOI] [PubMed] [Google Scholar]
  14. Finn A., Morgan B. P., Rebuck N., Klein N., Rogers C. A., Hibbs M., Elliott M., Shore D. F., Evans T. W., Strobel S. Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1996 Feb;111(2):451–459. doi: 10.1016/s0022-5223(96)70456-7. [DOI] [PubMed] [Google Scholar]
  15. Greally P., Hussain M. J., Vergani D., Price J. F. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child. 1994 Jul;71(1):35–39. doi: 10.1136/adc.71.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Greally P., Hussein M. J., Cook A. J., Sampson A. P., Piper P. J., Price J. F. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child. 1993 Mar;68(3):389–392. doi: 10.1136/adc.68.3.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Khan T. Z., Wagener J. S., Bost T., Martinez J., Accurso F. J., Riches D. W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075–1082. doi: 10.1164/ajrccm/151.4.1075. [DOI] [PubMed] [Google Scholar]
  18. Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
  19. Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  20. Konstan M. W., Hilliard K. A., Norvell T. M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994 Aug;150(2):448–454. doi: 10.1164/ajrccm.150.2.8049828. [DOI] [PubMed] [Google Scholar]
  21. Kronborg G., Hansen M. B., Svenson M., Fomsgaard A., Høiby N., Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol. 1993 May;15(5):292–297. doi: 10.1002/ppul.1950150506. [DOI] [PubMed] [Google Scholar]
  22. MacKenzie C. A., Weinberg E. G., Tabachnik E., Taylor M., Havnen J., Crescenzi K. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr. 1993 Oct;152(10):856–860. doi: 10.1007/BF02073387. [DOI] [PubMed] [Google Scholar]
  23. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  24. McElvaney N. G., Nakamura H., Birrer P., Hébert C. A., Wong W. L., Alphonso M., Baker J. B., Catalano M. A., Crystal R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nickerson B. G., Lemen R. J., Gerdes C. B., Wegmann M. J., Robertson G. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 1980 Dec;122(6):859–866. doi: 10.1164/arrd.1980.122.6.859. [DOI] [PubMed] [Google Scholar]
  26. Nikolaizik W. H., Schöni M. H. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr. 1996 Feb;128(2):271–274. doi: 10.1016/s0022-3476(96)70407-9. [DOI] [PubMed] [Google Scholar]
  27. O'Connor C. M., Gaffney K., Keane J., Southey A., Byrne N., O'Mahoney S., Fitzgerald M. X. alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1665–1670. doi: 10.1164/ajrccm/148.6_Pt_1.1665. [DOI] [PubMed] [Google Scholar]
  28. Ramsey B. W., Boat T. F. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr. 1994 Feb;124(2):177–192. doi: 10.1016/s0022-3476(94)70301-9. [DOI] [PubMed] [Google Scholar]
  29. Richman-Eisenstat J. Cytokine soup: making sense of inflammation in cystic fibrosis. Pediatr Pulmonol. 1996 Jan;21(1):3–5. doi: 10.1002/1099-0496(199601)21:1<3::aid-ppul1950210103>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  30. Rosenthal M., Bain S. H., Cramer D., Helms P., Denison D., Bush A., Warner J. O. Lung function in white children aged 4 to 19 years: I--Spirometry. Thorax. 1993 Aug;48(8):794–802. doi: 10.1136/thx.48.8.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Russell G. Inhaled corticosteroid therapy in children: an assessment of the potential for side effects. Thorax. 1994 Dec;49(12):1185–1188. doi: 10.1136/thx.49.12.1185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Salva P. S., Doyle N. A., Graham L., Eigen H., Doerschuk C. M. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol. 1996 Jan;21(1):11–19. doi: 10.1002/(SICI)1099-0496(199601)21:1<11::AID-PPUL2>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  33. Schiøtz P. O., Jørgensen M., Flensborg E. W., Faerø O., Husby S., Høiby N., Jacobsen S. V., Nielsen H., Svehag S. E. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand. 1983 Mar;72(2):283–287. doi: 10.1111/j.1651-2227.1983.tb09712.x. [DOI] [PubMed] [Google Scholar]
  34. van Haren E. H., Lammers J. W., Festen J., Heijerman H. G., Groot C. A., van Herwaarden C. L. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995 Mar;89(3):209–214. doi: 10.1016/0954-6111(95)90249-x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES